Dox-NP® (5mL vial) | 300105

Dox-NP® (Liposomal Encapsulated Doxorubicin)




All Prices in US Dollars
Quantity discounts may be available at the 5 and 10 count level.
Contact customer service for a quote.
Add your chosen unit to the shopping cart and adjust the quantity to see the discount.

To purchase larger quantities of this product please contact our Customer Service Department

  • Product
  • Data
  • Downloads
  • Reference
Concentration: 2 mg/ml doxorubicin HCl at pH 6.5-6.8, in 10 mM histidine buffer, with 10% w/v sucrose.
Particle size and shape: Dox-NP™ mean particle size is 80 to 90 nm, with very small poly-dispersity value
Purity: ≥90% of the drug is encapsulated in the long-circulating, pegylated, liposomes.
Formulation: The long-circulating, pegylated, liposomal carrier is composed of N-(carbonyl-ethoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg/ml; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg/ml; cholesterol, 3.19 mg/ml, ammonium sulfate, approximately 2 mg/ml; histidine as a buffer; hydrochloric acid or sodium hydroxide for pH control; and sucrose to maintain isotonicity. Dox-NP™ is provided as a sterile, translucent, red liposomal dispersion in single-use, 2 ml or 5 ml vials.
Buffer: 10 mM histidine buffer, pH 6.5-6.8, with 10% w/v sucrose.
Recommended applications: intravenous (i.v.) injection in flank or orthotopic animal models of cancer.
Storage conditions: Store undiluted at 2°-8° C. Do Not Freeze.
1 Years
Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist 2007 12:114-123.Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res. 2011, 3: 219-225.Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene- glycol coated liposomes. Cancer Res. 1994, 54: 987-992.Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target. 2002, 10:539-548.Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin. Oncol. 2001 19: 3312-3322.Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001, 24: 903-920.Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003, 42: 419-436.Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997, 54 (S4): 15-21.Charrois GJ, Allen TM. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther. 2003, 306:1058-1067.Barenholz. Y. Doxil® – The First FDA-Approved Nano-Drug: Lessons Learned. J Controlled Release 2012 in Press